Figure 2.

Progression‐free survival by lines of therapy and genomic subgroups in the ibrutinib arm (ITT population). (A) Analysis by number of prior lines of therapy. (B) Analysis by del(17p) and del(11q)*. (C) Analysis by CK. (D) Analysis by IGHV mutation status. (E) Analysis by TP53 mutation status. (F) Analysis by del(17p) and/or TP53 mutation status. CI, confidence interval; CK, complex karyotype; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy‐chain variable region gene; NE, not estimable; NR, not reached; PFS, progression‐free survival. *Genomic abnormalities by FISH cytogenetics were categorized according to Döhner hierarchical classification